Ascletis Pharma (HKG:1672) said it has dosed the first patients in its US clinical study for the combination of ASC47 and semaglutide for weight loss patients who do not have type 2 diabetes.
ASC47 is indicated for obese patients and adipose tissue or body fat, according to a Tuesday filing with the Hong Kong bourse.
The drug reduced body weight by about 57% and preserved muscles in diet-induced obese mouse models, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。